Android app on Google Play

Unusual 11 Mid-Day Movers 01/09: (ININ) (KGJI) (CSIQ) Higher; (SCHS) (PPHM) (NUVA) Lower

January 9, 2013 1:01 PM EST Send to a Friend
Get Alerts SCHS Hot Sheet
Trade SCHS Now!
Join SI Premium – FREE
School Specialty, Inc. (Nasdaq: SCHS) 28.4% LOWER; reported entering into a forbearance agreement. For more color, click here.

Interactive Intelligence Group Inc. (Nasdaq: ININ) 19.2% HIGHER; reported strong preliminary revenue for the fourth-quarter and fiscal 2012 periods. Click here for more color.

Kingold Jewelry, Inc. (Nasdaq: KGJI) 15.1% HIGHER; Kingold moving back above $1.20 on volume today.

Canadian Solar Inc. (Nasdaq: CSIQ) 13.4% HIGHER; announced that its submission of the 148 MW solar park PV project in southern Brandenburg, Germany was named the 2012 winner of the Solar Project of the Year Award by POWER-GEN International.

Rosetta Genomics Ltd. (Nasdaq: ROSG) 13.2% HIGHER; reported that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis. For more color, click here.

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) 12.5% LOWER; seeing some selling after ripping 80 percent higher on Monday. Click here for more color on the event.

NuVasive, Inc. (Nasdaq: NUVA) 12.3% LOWER; announced preliminary unaudited revenue results for the full year ended December 31, 2012. NuVasive anticipates full year 2012 revenue of approximately $619 million. The unaudited results compare to previously issued guidance of $601 million to $606 million in revenue for the full year 2012.

Trina Solar (NYSE: TSL) 11.9% HIGHER; continuing higher on sentiment that China will add solar capacity over the near term. For more color, click here.

Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) 11.1% LOWER; initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis. CTI might also be pulling back after a 25 percent gain on Tuesday.

Mistras Group (NYSE: MG) 10.5% LOWER; reported Q2 EPS of $0.32, in-line with the analyst estimate of $0.32. Revenue for the quarter came in at $137.7 million versus the consensus estimate of $141.34 million. Sees FY2013 revenue of $525-$535 million, versus the consensus of $535.64 million.

Apollo Group (Nasdaq: APOL) 8.4% LOWER; reported strong Q1 results, but drops in enrollment along with light revenue expectations for FY13 are giving investors pause.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Unusual 11 Mid-Day Movers

Add Your Comment